Bionomics Balance Sheet Health

Financial Health criteria checks 6/6

Bionomics has a total shareholder equity of $17.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $22.9M and $5.8M respectively.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	n/a
Cash	US$8.08m
Equity	US$17.07m
Total liabilities	US$5.85m
Total assets	US$22.92m

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: B1N0's short term assets ($8.4M) exceed its short term liabilities ($2.6M).

Long Term Liabilities: B1N0's short term assets ($8.4M) exceed its long term liabilities ($3.3M).

Debt to Equity History and Analysis

Debt Level: B1N0 is debt free.

Reducing Debt: B1N0 has no debt compared to 5 years ago when its debt to equity ratio was 111.6%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: B1N0 has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: B1N0 is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.

Bionomics Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Bionomics Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Recent updates

Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Bionomics Limited Announces Resignation of Aaron Weaver from the Board of Directors

New minor risk - Financial data availability

Bionomics Limited Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

Bionomics Initiates Affirm-1, A Phase 3 Clinical Trial with Bnc210 for Social Anxiety Disorder

Bionomics Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

New major risk - Shareholder dilution

High number of new and inexperienced directors

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

First half 2024 earnings released: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)

New minor risk - Shareholder dilution

New major risk - Financial position

New major risk - Market cap size

Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023

Bionomics Limited, Annual General Meeting, Nov 30, 2023

Bionomics Limited Announces Successful and Favorable Outcomes of an End-Of-Phase 2 Meeting (Eop2) Meeting with the U.S. Food and Drug Administration

New minor risk - Financial position

Full year 2023 earnings released: AU$3.60 loss per share (vs AU$0.016 loss in FY 2022)

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies